JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 12 May 2006. doi:10.1136/jcp.2006.036699
Journal of Clinical Pathology 2007;60:50-56
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.036699v1
60/1/50    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zheng, H.
Right arrow Articles by Takano, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, H.
Right arrow Articles by Takano, Y.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Liver Cancer

ORIGINAL ARTICLE

Expression of KAI1 and tenascin, and microvessel density are closely correlated with liver metastasis of gastrointestinal adenocarcinoma

Huachuan Zheng1, Koichi Tsuneyama1, Chunmei Cheng2, Hiroyuki Takahashi1, Zhengguo Cui1, Kazuhiro Nomoto1, Yoshihiro Murai1, Yasuo Takano1

1 Department of Pathology (1), Faculty of Medicine, University of Toyama, Toyama, Japan
2 Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, California, USA

Correspondence to:
Dr K Tsuneyama
Department of Pathology (1) and 21st Century COE Program, Faculty of Medicine, University of Toyama, Sugitani 2630, Toyama, Japan; ktsune{at}ms.toyama-mpu.ac.jp Aim: To seek good markers to predict invasion and metastasis of gastrointestinal adenocarcinoma (GIA).

Methods: Expression of KAI1 and tenascin were examined on tissue microarrays containing gastric adenocarcinoma (n = 98), colorectal adenocarcinoma (n = 125), gastric adjacent non-cancerous mucosa (n = 95) and colorectal adjacent non-cancerous mucosa (n = 112) by immunostaining. Microvessel density (MVD) in GIA was labelled using anti-CD34 antibody by immunostaining. Expression of KAI1 and tenascin, and MVD were compared with clinicopathological features of tumours, including PTEN (phosphatase and tensin homology deleted from human chromosome 10) and EMMPRIN (extracellular matrix metalloproteinase inducer) expression.

Results: KAI1 expression was higher in GIAs than in their adjacent non-cancerous mucosa (p<0.05). KAI1 and tenascin expression showed a significantly negative association with liver metastasis of GIA (p<0.05), but not with depth of invasion, venous invasion or lymph node metastasis (p>0.05). A significantly negative relationship was observed between EMMPRIN and tenascin expression in GIA (p<0.05). MVD was positively correlated with depth of invasion, venous invasion, lymph node metastasis and liver metastasis of tumours (p<0.05), whereas it was negatively correlated with PTEN expression (p<0.05).

Conclusions: Up-regulated KAI1 expression may play an important part in malignant transformation of gastrointestinal epithelial cells. Reduced expression of KAI1 and tenascin might underlie the molecular basis of liver metastasis of GIA. Angiogenesis is a key event in the invasion and metastasis of GIA. These markers might be used to indicate liver metastasis of GIA in clinicopathological practice.


Abbreviations: DAB, 3,3'-diaminobenzidine; ECM, extracellular matrix; EMMPRIN, extracellular matrix metalloproteinase inducer; GIA, gastrointestinal adenocarcinoma; H&E, haematoxylin and eosin; MMPs, matrix metalloproteinases; MVD, microvessel density; PTEN, phosphatase and tensin homology deleted from human chromosome 10; TMA, tissue microarray; TM4SF, transmembane glycoproteins of tetraspanins family; VEGF, vascular epithelial growth factor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.